These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 37891433)

  • 1. Transporting Comparative Effectiveness Evidence Between Countries: Considerations for Health Technology Assessments.
    Turner AJ; Sammon C; Latimer N; Adamson B; Beal B; Subbiah V; Abrams KR; Ray J
    Pharmacoeconomics; 2024 Feb; 42(2):165-176. PubMed ID: 37891433
    [TBL] [Abstract][Full Text] [Related]  

  • 2. R WE ready for reimbursement? A round up of developments in real-world evidence relating to health technology assessment: part 10.
    Simpson A; Ramagopalan SV
    J Comp Eff Res; 2023 Jan; 12(1):e220194. PubMed ID: 36453665
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Algorithms and heuristics of health technology assessments: A retrospective analysis of factors associated with HTA outcomes for new drugs across seven OECD countries.
    Kanavos P; Visintin E; Gentilini A
    Soc Sci Med; 2023 Aug; 331():116045. PubMed ID: 37450991
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Informing a decision framework for when NICE should recommend the use of health technologies only in the context of an appropriately designed programme of evidence development.
    Claxton K; Palmer S; Longworth L; Bojke L; Griffin S; McKenna C; Soares M; Spackman E; Youn J
    Health Technol Assess; 2012; 16(46):1-323. PubMed ID: 23177626
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The GRACE Checklist: A Validated Assessment Tool for High Quality Observational Studies of Comparative Effectiveness.
    Dreyer NA; Bryant A; Velentgas P
    J Manag Care Spec Pharm; 2016 Oct; 22(10):1107-13. PubMed ID: 27668559
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Health technology assessment of medical devices: What is different? An overview of three European projects.
    Schnell-Inderst P; Mayer J; Lauterberg J; Hunger T; Arvandi M; Conrads-Frank A; Nachtnebel A; Wild C; Siebert U
    Z Evid Fortbild Qual Gesundhwes; 2015; 109(4-5):309-18. PubMed ID: 26354131
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modelling approaches for histology-independent cancer drugs to inform NICE appraisals: a systematic review and decision-framework.
    Murphy P; Glynn D; Dias S; Hodgson R; Claxton L; Beresford L; Cooper K; Tappenden P; Ennis K; Grosso A; Wright K; Cantrell A; Stevenson M; Palmer S
    Health Technol Assess; 2021 Dec; 25(76):1-228. PubMed ID: 34990339
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The use of economic evaluations in NHS decision-making: a review and empirical investigation.
    Williams I; McIver S; Moore D; Bryan S
    Health Technol Assess; 2008 Apr; 12(7):iii, ix-x, 1-175. PubMed ID: 18373906
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Effectiveness of Integrated Care Pathways for Adults and Children in Health Care Settings: A Systematic Review.
    Allen D; Gillen E; Rixson L
    JBI Libr Syst Rev; 2009; 7(3):80-129. PubMed ID: 27820426
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Decision-makers' preferences for approving new medicines in Wales: a discrete-choice experiment with assessment of external validity.
    Linley WG; Hughes DA
    Pharmacoeconomics; 2013 Apr; 31(4):345-55. PubMed ID: 23516033
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Why do health technology assessment coverage recommendations for the same drugs differ across settings? Applying a mixed methods framework to systematically compare orphan drug decisions in four European countries.
    Nicod E
    Eur J Health Econ; 2017 Jul; 18(6):715-730. PubMed ID: 27538758
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world evidence in health technology assessment of high-risk medical devices: Fit for purpose?
    Klein P; Blommestein H; Al M; Pongiglione B; Torbica A; Groot S
    Health Econ; 2022 Sep; 31 Suppl 1(Suppl 1):10-24. PubMed ID: 35989520
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Health Technology Assessment (HTA) Case Studies: Factors Influencing Divergent HTA Reimbursement Recommendations in Australia, Canada, England, and Scotland.
    Allen N; Walker SR; Liberti L; Salek S
    Value Health; 2017 Mar; 20(3):320-328. PubMed ID: 28292476
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multi-gene Pharmacogenomic Testing That Includes Decision-Support Tools to Guide Medication Selection for Major Depression: A Health Technology Assessment.
    Ontario Health (Quality)
    Ont Health Technol Assess Ser; 2021; 21(13):1-214. PubMed ID: 34484487
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The assessment and appraisal of regenerative medicines and cell therapy products: an exploration of methods for review, economic evaluation and appraisal.
    Hettle R; Corbett M; Hinde S; Hodgson R; Jones-Diette J; Woolacott N; Palmer S
    Health Technol Assess; 2017 Feb; 21(7):1-204. PubMed ID: 28244858
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluating high-cost technologies - no need to throw the baby out with the bathwater.
    Sagoo GS; Robinson T; Coughlan D; Meader N; Rice S; Vale L
    Expert Rev Pharmacoecon Outcomes Res; 2023; 23(10):1177-1183. PubMed ID: 37755333
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.